Analysis of the association between the serum autoantibodies and the prognosis of patients with pancreatic cancer

Analysis of the association between the serum autoantibodies and the prognosis of patients with pancreatic cancer - The serum autoantibodies and the prognosis of patients with pancreatic cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000011478

Enrollment

200

Registered

2013-08-13

Start date

2013-05-28

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreatic cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Written informed consent is acquired from all patients or proxies ofthe patients. 2.The age of the patients is from 20 to 80. 3.Patients with pathologically proven pancreatic cancer 4.Patients who receive surgical resection, chemotherapy, and/or chemoradiotherapy

Exclusion criteria

Exclusion criteria: 1.Patients with an active concomitant malignancy 2.Estimated suvaival<1 month 3.Patients with severe heart, respiratory or liver failure 4.Patients with administration of steroids, immunosuppresive drugs or biological products 5.Inappropriate patients for entry on this study in the judgement of the investigator

Design outcomes

Primary

Measure	Time frame
Overall survival	—

Secondary

Measure	Time frame
Disease-free survival	—

Countries

Japan

Contacts

Public ContactHironari Kato

Okayama University Graduate School of Medicine Dentistry and Pharmaceutical Sciences Gastroenterology and Hepatology

drkatocha@yahoo.co.jp+81-86-235-7219

Outcome results